BioCryst Pharma (BCRX) Prices 18.7M Share Common Offering at $4.50/Sh; Announces Pricing of Pre-Funded Warrants Offering

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to BioCryst Pharma (BCRX) Prices 18.7M Share Common Offering at $4.50/Sh; Announces Pricing of Pre-Funded Warrants Offering

Call Buying Activity Continues in BioCryst Pharma (BCRX), Targeting Upside in Shares Through July -Susquehanna

May 28, 2020 3:01 PM EDT

Susquehanna options strategist Alison Edwards notes call buying activity in BioCryst Pharma (NASDAQ: BCRX), as investors bought ~12k July 9 calls, adding to roughly 20K of the calls bought since early last week. A position of about 30k calls gives investors the right... More

After-Hours Stock Movers 05/27: (PHAS) (SMTC) (TOL) Higher; (IOVA) (ARNA) (PLT) Lower (more...)

May 27, 2020 5:41 PM EDT

Today's After-Hours Stock Movers:

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) 74.4% HIGHER; announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

Semtech (NASDAQ: SMTC) 13.6% HIGHER; reported Q1 EPS of $0.35, $0.03 better than the analyst estimate of $0.32. Revenue for the quarter came in at $132.7 million versus the consensus estimate of $129.28 million. Semtech sees Q2 2021 EPS of... More

BioCryst Pharma (BCRX) Commences Public Offering of Common Stock and Pre-Funded Warrants

May 27, 2020 4:08 PM EDT

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $100 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering. As... More